期刊文献+

CD29和EGFR在乳腺癌中的表达及临床意义

Expression and Clinical Significance of CD29 and EGFR in Breast Cancer
下载PDF
导出
摘要 目的:探讨粘附因子CD29和表皮生长因子受体(EGFR)在乳腺癌中的表达情况和临床意义。方法:收集乳腺癌标本98例,腺病52例。利用免疫组织化学方法检测CD29与EGFR的阳性表达率,并分析两者的相关性。结果:CD29和EGFR在腺病中的阳性表达率分别为5.8%(3/52)和3.8%(2/52),在乳腺癌中的阳性表达率分别为70.4%(69/98)和62.2%(61/98),在同一病种两者的阳性表达率比较,差异均无统计学意义(P>0.05),但两者在乳腺癌中的阳性表达率均明显高于腺病,差异均有统计学意义(P<0.05)。浸润性癌阳性表达率均高于原位癌(P<0.05),高级别癌的阳性表达率均高于低级别癌(P<0.05),有淋巴结转移的阳性表达率均高于无转移(P<0.05)。结论:CD29和EGFR的高表达与乳腺癌的发生、分化及转移有相关性,而且两者表达均呈正相关,因此检测乳腺癌的CD29和EGFR对治疗及预后有指导作用。 Objective: To investigate the expression and clinical significance of CD29 and epidermal growth factor receptor ( EGFR ) in breast cancer.Method: Collected 98 cases of breast cancer specimens, 52 cases of adenomy0sis.The positive expression rates of CD29 and EGFR were detected by immunohistochemistry, and the correlation between them was analyzed.Result: The positive expression of CD29 and EGFR in adenosis rates were 5.8% ( 3/52 ) and 3.8% ( 2/52 ), the positive expression rate in breast cancer were 70.4% ( 69/98 ) and 62.2% ( 61/98 ), there were no significant differences in the positive expression rate of the same disease ( P〉0.05 ), but the positive expression both in breast cancer rates were significantly higher than those of adenosis, the differences were statistically significant ( P〈0.05 ) .The positive expression rate of invasive carcinoma was higher than that in situ carcinoma ( P〈0.05 ), and the positive expression rate of advanced carcinoma was higher than that of low grade carcinoma ( P〈0.05 ), the positive expression rate Of lymph node metastasis was higher than that of non metastasis ( P〈0.05 ) .Conclusion: The high expression of CD29 and EGFR are correlated with the occurrence, differentiation and metastasis of breast cancer, and there is a positive correlation between them, therefore, the detection of CD29 and breast cancer has a guiding effect on the treatment and prognosis.
出处 《中国医学创新》 CAS 2017年第12期51-54,共4页 Medical Innovation of China
基金 宝安区科技计划项目(2012015)
关键词 乳腺癌 粘附因子CD29 表皮生长因子受体 Breast cancer Adhesion molecule CD29 Epidermal growth factor receptor
  • 相关文献

参考文献1

二级参考文献114

  • 1Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009,9: 463-475.
  • 2Hynes NE and MacDonald G. ErbB receptors and signaling pathways in cancer. CurrOpin Cell Bioi 2009, 21: 177-184.
  • 3Hynes NE and Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5: 341-354.
  • 4DeFazio A, Chiew YE, Sini RL, Janes PWand Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000,87: 487 -498.
  • 5Olayioye MA, Neve RM, Lane HA and Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000,19: 3159.
  • 6Ogiso H, Ishitani R, Nureki 0, Fukai S, Yamanaka M, Kim JH and Saito K, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110: 775-787.
  • 7Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ and Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003, 11: 507-517.
  • 8Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ and Lemmon MA, et al. An open-and-shut case? Recent insights into the activation ofEGFlErbB receptors. Mol Cell 2003, 12: 541-552.
  • 9Cho HS and Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297: 1330-1333.
  • 10Graus-Porta D, Beerli RR, Daly JM and Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997,16: 1647-1655.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部